Acute back pain is the constant and sharp pain at the back that occurs when person falls or lifts something heavy and gradually becomes worse. According to researchers, acute back pain can be caused by ruptured disks, spasms, disk breakdown, and tense muscles. Acute back pain is also associated with various diseases and conditions such as scoliosis, arthritis, pregnancy, kidney stones, endometriosis, spondylolisthesis, and infections. Acute back pain can be diagnosed by blood test, computed tomography, magnetic resonance imaging, and X-rays. Thar Pharmaceuticals, Inc. is in the process of developing T109 as a non-narcotic therapy, for the treatment of acute back pain. Nektar Therapeutics is in the process of developing NKTR-181 as a selective mu-opioid agonist for the treatment of acute back pain. Some of the companies having the pipeline of acute back pain include Nektar Therapeutics, Thar Pharmaceuticals, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.